Trials / Completed
CompletedNCT02640547
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 394 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to provide evidence of the effectiveness and obtain patient reported outcomes (PRO) and work productivity data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), +/- dasabuvir (DSV), +/- ribavirin (RBV) in chronic hepatitis C virus infected patients.
Conditions
Timeline
- Start date
- 2015-11-26
- Primary completion
- 2017-03-29
- Completion
- 2017-03-29
- First posted
- 2015-12-29
- Last updated
- 2018-10-17
- Results posted
- 2018-10-17
Source: ClinicalTrials.gov record NCT02640547. Inclusion in this directory is not an endorsement.